Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542

Japan

Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

Buzz

Evaluate and EP Vantage Mentioned in the Press or Industry Reports

May 2017

Large acquisitions to expand into the US market. The sense of urgency a major generic maker holds. (Sawai) - Toyokeizai, May 13, 2017 

April 2017

Monday Is D-Day For AEZS, Watch Out For MRUS, FDA Nod For RDUS & Takeda - MarketInsider, April 30, 2017
“According to market research firm EvaluatePharma, Kevzara could garner peak sales of $1.8 billion by 2020…”

 

Kaneka increases raw materials for biopharmaceuticals, and invests 5 billion yen for production for Europe and US pharmaceutical companies - Nikkei, April 24, 2017

 

Самые высокодоходные компании мирового фармрынка за 2016 год - GMP News, April 28, 2017
“ Согласно прогнозу компании «EvaluatePharma», этот препарат в 2022 г. займет 3-е место в рейтинге самых продаваемых блокбастеров для лечения онкологических заболеваний в мире с прогнозируемым доходом от продаж на уровне 8,29 млрд дол…”


Regeneron's Eylea success makes it 'uniquely exposed' to Medicare payment shift - FiercePharma, April 27, 2017
“According to a new report from EvaluatePharma’s EP Vantage, the U.S. health program spends more on Regeneron’s highly successful eye treatment than any other drug injected at doctors’ offices…"


Pharma launch challenges will only get worse - Tribeca Knowledge, April 27, 2017
“For the top 10 medicines in the US last year, the average annual cost per patient for an orphan drug was $140,443 compared with $27,756 for a non-orphan product, notes a report by Evaluate Pharma…”


FDA Drug Approvals up Sharply in Q1 - Chemanager, April 24, 2017
“After a major slowdown in 2016, new drug approvals by the US Food and Drug Administration rose sharply in the first quarter of 2017, according to a report by EP Vantage. Up to mid-April, the authority had approved more new drugs than during the same quarter of during the past six years…”

 

Look back at pharma news to Apr 21 - The Pharma Letter, April 23, 2017
“Not putting all your eggs in one basket has clear benefits, said EP Vantage, the editorial arm of the Evaluate group discussing new data on Ultragenyx’ burosumab…”

 

18 Drugs To Lose Patents In 2017; Could Jeopardize $26.5B For Big Pharma - TalkMarkets, April 22, 2017
“EvaluatePharma has reported that $55 billion in total drug sales lost patent protection that year…”

 

Fujifilm Corporation, reinforcing the market to biopharmaceuticals in the US and UK, and 14-billion-yen investment on contract company - Nikkei, April 18, 2017

 

Making The Cut - AJP, April 16, 2017
“However, analysts are still predicting a range of new ‘blockbuster’ drug launches. Heading the list, according to EP Vantage’s 2017 preview, which ranks the year’s rollouts by 2022 sales, is Ocrevus (ocrelizumab), a multiple sclerosis drug from Roche…”

 

Best Ms Drug - New York City High Tech News, April 15, 2017
“At the top of the list, according to EP Vantage’s 2017 preview, which ranks the year’s rollouts by 2022 sales, is Ocrevus (ocrelizumab), the Roche multiple sclerosis drug that’s promising to shake things up in more ways than one...”


Honestly, Not Such a Good Friday - My Cancer Journey, April 15, 2017
“In this regard, in an interview with EP Vantage earlier this month, Luciano Rossetti, Merck KGaA’s head of R&D, told EP Vantage that M7824 is “the most exciting clinical asset in our pipeline right now” adding that it has yielded “spectacular” early data…”

 

Not sold: FDA demands more data on Eli Lilly’s rheumatoid arthritis drug - MedCity News, April 14, 2017
“Despite the cluster of therapies now available for RA, EvaluatePharma had projected sales of Olumiant to reach nearly $1.8 billion per year by 2022…”

 

After attracting star CEO Hung, Axovant looks to raise $125m - Pharmaphorum, April 12, 2017
“However even a relatively modest success could open up a huge market for Axovant – last year analysts EP Vantage ranked the molecule as the most valuable unpartnered asset, estimating its net present value as $5.2 billion...”

 

Neurocrine nabs Ingrezza OK to kick-start tardive dyskinesia market, with Teva waiting in the wings - FiercePharma, April 12, 2017
“EP Vantage, for one, predicts that launch has blockbuster potential, pegging the med’s 2022 sales at $1.3 billion….”


Nothing’s Gonna Stop Neurocrine Biosciences Now: Shares Jumped on FDA Approval of the First and Only Drug to Treat Tardive Dyskinesia for Adults - BioSpace, April 12, 2017
“EvaluatePharma has also projected blockbuster status…”

 

Nine blockbuster drugs to watch are making their debut, aiming at a $16B prize in 2021 - Endpoints, April 11, 2017
“EvaluatePharma put together their list of top drugs in the pipeline, and came up with 15 prospective blockbusters…"

 

Neurocrine Bioscience Receives FDA Approval For Ingrezza For Treatment Of TD; Stock Jumps 19% - TalkMarkets, April 11, 2017
“EvaluatePharma has also tracked a blockbuster future for this drug as well, designed to treat involuntary movements spurred by the prolonged use of antipsychotics. Huntington’s chorea is a related condition involving involuntary twisting and writhing….”

 

Continua la crescita del mercato dei farmaci orfani - Notizaro Chimico Farmaceutico, April 11, 2017
“Quest’anno abbiamo di nuovo evidenziato che sono le big pharma che dominano il settore”, ha spiegato l’analista Lisa Urquhart a proposito dei risultati del quarto rapporto “EvaluatePharma Orphan Drug Report 2017”, secondo il quale sette delle dieci maggiori aziende del settore per volume di vendita sono grandi player farmaceutici globali…”

 

MedNess: FDA approvals,rejections, M&A and more… - Club SciWri, April 10, 2017
“According to EvaluatePharma, Zejula is one of the top drug launches of 2017 with 2022 sales expectations of $1.9 billion…”

 

5 trends shaping rare disease drug development - BioPharma Dive, April 10, 2017
“As more rare disease medicines make it to market, worldwide sales of the orphan drugs have grown rapidly, increasing at a faster rate than sales of non-orphans according to Evaluate Pharma, a life sciences intelligence firm…”

 

Why drugs like these for ‘orphan’ diseases are a booming business with colossal costs for patients - The Globe and Mail, April 8, 2017
“EvaluatePharma, a U.S. company that analyzes the pharmaceutical and biotechnology sectors, predicts that orphan-drug sales will grow by 11 per cent a year over the next five years, twice the rate of conventional prescription drugs…”

 

Look back at pharma news to Apr 7 - The Pharma Letter, April 8, 2017
“The move by Japan’s largest drugmaker, Astellas Pharma  to buy Ogeda seems more driven by a wish to own a particular asset than by expansion plans, commented EP Vantage, the editorial arm of the Evaluate group…”
 
6 trends shaking the pharmaceutical market - The Network Effect, April 7, 2017
 “According to EvaluatePharma, “World Preview 2018,” between 2012 and 2018, generic erosion was projected to wipe out about $148 billion in pharmaceutical revenues…”

 

The Bay Area Pharma Stock Investors Could Buy and Hold for the Next 20 Years - BioSpace, April 7, 2017
“Because BioMarin focuses on rare and ultra-rare diseases, the prices—and hence the margins—on their drugs are sky high. Budwell points out that EvaluatePharma’s most recent industry report indicates that orphan drugs will have 20 percent of the total prescription market by 2022. And BioMarin is one of the top orphan drugmakers. ..”

 

3 Stocks We'd Buy and Hold for the Next 20 Years - The Motley Fool, April 6, 2017
“In fact, EvaluatePharma's latest industry report has orphan drugs grabbing over 20% of the total prescription drug market by 2022…”

*Also in Madison.com 

 

Changing Expectations in the Pharma Outsourcing Market - Interphex Blog, April 6, 2017
“The global pharmaceutical market is currently expanding at a healthy compound annual growth rate (CAGR) of 6.3% according to EvaluatePharma…”

 

Could the Ranbaxy whistleblower head the FDA office in India?; Reprieve for GSK as Mylan’s Advair generic gets delayed - PharmaCompass, April 6, 2017
“EvaluatePharma has pegged consensus forecasts of revenue for 2022 at US $ 4 billion for this therapy. Dupixent is expected to land about a billion dollars behind Ocrevus…”

 

By Engaging Payers Before Setting Price, One Drug Company Wins Praise Despite $37K-A-Year Cost - KHN, April 5, 2017
“Analysts expect both drugs could top $4 billion in annual revenues by 2022, according to a recent analysis from the forecasting firm Evaluate Pharma…”

 

FDA approves Teva’s Huntington’s Disease drug - Pharmaphorum, April 5, 2017
“Analysts Evaluate Pharma predict sales of more than $3.4 billion in 2022, making this an important drug for the Israel-based pharma as its big-selling Copaxone multiple sclerosis drug comes under threat from generics…”

 

Have we finally turned a corner with drug pricing? - MedCity News, April 4, 2017
“Based on EvaluatePharma’s predictions, Ocrevus and Dupixent will be the highest grossing drugs to enter the market in 2017. The pricing on those drugs matters…”


Replicel (Rp.V) Targeting Multiple Billion Dollar Markets With Autologous Cell Therapies - SCR, April 4, 2017
“The skin rejuvenation market is enormous. Botox®, which is used to treat facial wrinkles, had 2015 worldwide sales of $2.8 billion in 2015 (EvaluatePharma)…”

 

Firms inject funds into biopharmaceuticals - The Japan News, April 4, 2017
“The British research firm EvaluatePharma estimates that the global market for biopharmaceuticals will reach $200 billion in 2016, about 1.4 times larger than five years ago…”


Behind Rare Disease Day 2017 - Pharmafile, April 3, 2017
“Some of the most expensive treatments offered in the world are those that treat rare diseases; according to a report on orphan drugs by EvaluatePharma, the average price tag in the US comes in at $111,820 per year compared with $23,331 for more regular medicines…”

 

Kite keeps pressure on Novartis with CAR-T filing - Pharmaphorum, April 3, 2017
“According to analyst Evaluate Pharma, axicabtagene ciloleucel is the most valuable orphan drug in the pharma pipeline…”


Brief: Report: Market Share Of Orphan Drugs Could Top 20 Percent Of Global Market By 2022 - IP Watch, April 3, 2017
“EvaluatePharma, a company headquartered in London which provides consensus forecasting to the pharmaceutical and biotechnology industries, has released its Orphan Drug Report 2017…”

 

Pfizer keeps nose ahead of rivals with new Ibrance approval - PMLive, April 3, 2017
“EvaluatePharma analysts have suggested Ibrance will become a mega-blockbuster with sales of $6bn-plus in 2022, consigning its CDK4/6/rivals - still tipped for big sales - into a scrabble for second place…”

 

Newsmakers: Peter Soelkner - Contract Pharma, April 3, 2017
“According to the Evaluate Pharma, World Preview 2016, Outlook to 2022, from the period of September 2016 until 2022, sales volume in orphan drugs is expected to increase significantly, effectively doubling…”

 

Look back at pharma news week to Mar 31 - The Pharma Letter, April 2, 2017
“Roche now has the first approved drug for both the relapsing and primary progressive forms of multiple sclerosis in the shape of Ocrevus, noted EP Vantage, the editorial arm of the Evaluate group…”

 

Orphan Drug Surge Raises Regulatory and Development Challenges - Applied Clinical Trials, April 1, 2017
“Meanwhile, orphan drugs will account for more than 21% of worldwide brand-name prescription drug sales in 2022, up from 6% in 2000, according to an analysis by EvaluatePharma…”


Pharmapills puntata n.5. La crescita del mercato dei farmaci orfani secondo il report di EvaluatePharma - Carriera Nel Farmaceutico.com, April 2017
“Persone: Rino Rappuoli (GSK Vaccines), Pei-Yong Shi (Università del Texas di Galveston), Duncan M. Baird (Università di Cardiff), Lisa Urquhart (Evaluate Pharma), Kevin C. Gorman (Neurocrine Biosciences), Edward Cox (FDA), Andrea Fagiolini (Università di Siena)…”


I 10 FARMACI PIÙ ATTESI DEL 2017 - Farmivi, April 2017
“La società americana Evaluate Pharma ha stilato la classifica dei 10 farmaci che saranno lanciati nel corso del 2017 e che nel 2022  raggiungeranno i fatturati più elevati. E’ una previsione, si intende, ma fatta

da chi i conti li sa fare…”

 

КАК ЛЕКАРСТВА НОВОГО ПОКОЛЕНИЯ ИЗМЕНЯТ ГЛОБАЛЬНЫЙ РЫНОК ОНКОПРЕПАРАТОВ - Pharma.net.ua, April 2017
“По данным EvaluatePharma, ТОП-3 глобального рынка онкопрепаратов (L01 L02, по классификации ATC) в 2015 году был представлен блокбастерами Roche – Мабтерой (ритуксимаб), Герцептином (трастузумаб) и Авастином (бевацизумаб), впервые введенными в обращение в 1997, 1998 и 2004 годах соответственно и принесшими производителю в 2015 году около $20 млрд. В 2016 году этот расклад, если не брать в расчет выход аналогов этих препаратов, сохранился практически повсеместно. Но скоро все должно измениться…”

 

March 2017

Automation: A more reliable and scalable way to process samples in the biopharmaceutical lab - Laboratory Focus, March 31, 2017
“In a September 2016 publication by EvaluatePharma 1, they estimated by 2022, biologic drugs will contribute 50 per cent of the top 100 pharmaceutical product sales…”

 

Дайджест / Фармацевтический рынок » Рынок орфанных препаратов: какие факторы обусловливают рост? - Clinical-Pharmacy.ru, March 28, 2017
“Так, согласно отчету «Orphan Drug Report 2017» аналитической компании «Evaluate Pharma», если по итогам 2016 г. лавры лидера мирового рынка по объему продаж орфанных препаратов в денежном выражении принадлежали компании «Novartis», то к 2022 г. на данном посту ее, вероятно, сменит компания «Celgene»…”

 

Farmaceutico: previsioni per il 2017 secondo il report di EP Vantage CRA Secrets, March 27, 2017
“Eppure, gli esperti di Evaluate Pharma, editoriale indipendente con sede a Londra, hanno elaborato un report che presenta le previsioni per il 2017 relative al settore delle industrie pharma e biotech…”

 

Look back at pharma news to Mar 24The Pharma Letter, March 25, 2017
“Drugmakers, regulators and legislators have put enormous effort towards bringing abuse-proof painkillers to market over the past decade or more, with little to show for it, noted EP Vantage, the editorial arm of the Evaluate group…”

La industria avisa de la llegada de una “ola de biosimilares oncológicos”El Global.net, March 24, 2017
“Para 2022 se estima que alcanzará el 16,3 por ciento del total del mercado farmacéutico, superando los 190.000 millones de dólares, según el último informe publicado por Evaluate Pharma…”

GAO to Investigate FDA's Orphan Drug Program Medscape, March 23, 2017
“The rare-disease drugs have become increasingly popular with pharmaceutical and biotech companies and are expected to comprise 21.4 percent of worldwide prescription sales by 2022, not including generics, according to consulting firm EvaluatePharma’s 2017 orphan drug report…”

Biogen-sejr er gode nyheder for Forward Pharma Medwatch, March 23, 2017
“Og det er gode nyheder for det danske biotekselskab Forward Pharma, skriver EP Vantage…”

U.S. government plans to probe orphan drug programSpectrum, March 23, 2017
“They are expected to constitute 21.4 percent of worldwide prescription sales by 2022, not including generics, according to consulting firm EvaluatePharma’s 2017 orphan drug report…”

Week Nine Just FineMy Cancer Journey, March 22, 2017
“ In this regard, in an interview with EP Vantage earlier this month, Luciano Rossetti, Merck KGaA’s head of R&D, told EP Vantage that M7824 is “the most exciting clinical asset in our pipeline right now” adding that it has yielded “spectacular” early data. You can read the full interview by clicking here…”

ATF V: Iniating Coverage of Antibe Therapeutics Inc.; Developing Next Generation NSAIDS Complemented By Tissue Regeneration Subsidiary Zacks, March 22, 2017
“NSAIDS comprise one of the largest drug classes worldwide, with estimated sales of both prescription and non-prescription drugs approaching $9 billion in 2016 (EvaluatePharma)…”

Exclusive: Three Hepatitis C Drugs from Foreign Pharmaceuticals Close to Approval, Sources Say Caixin, March 22, 2017
“Since 2013, DAAs have become very popular, and their global sales have jumped from $5 billion in 2013 to $24 billion in 2015, according to pharmaceutical and biotechnology research firm EvaluatePharma…”

Look back at pharma news to Mar 17 The Pharma Letter, March 19, 2017
“FDA approval of the second CDK4/6 inhibitor, Novartis’ breast cancer drug Kisqali, has set up a battle against the current incumbent, Pfizer’s Ibrance, commented EP Vantage, the editorial arm of the Evaluate group. ..”

Weesgeneesmiddelen in de lift Vereniging Innovatieve Geneesmiddelen, March 17, 2017
“De markt voor weesgeneesmiddelen zal de komende jaren flink groeien, zo blijkt uit het Orphan Drug Report 2017 van EvaluatePharma…”

Mylan deal with Roche clears path to biosimilar Herceptin launchPMLive, March 14, 2017
“Despite the competition, EvaluatePharma has suggested that Roche's blockbuster products will still be bringing in good revenues for the foreseeable future, as biosimilars do not tend to cause the steep declines on brands as traditional generics…”

Rollout of Regeneron's new eczema drug could be most lucrative of the year Times Union, March 13, 2017
“Barely three months into the year, analysts are predicting the company's pending Dupixent drug could be the most lucrative pharmaceutical launch of 2017, with annual revenues topping $4.6 billion by 2022, according to EvaluatePharma, a biotech research group…”

German Merck, flying under Street’s radar, gets no respect; but not for long Monday Morning, March 13, 2017
“Luciano Rossetti, the German group’s head of R&D, said the bispecific fusion protein, known only under the designation M7824, “is the most exciting clinical asset in our pipeline right now,” according to EP Vantage…” 

Pfizer wins 1st round with marketing exec accused of stealing launch plans Awesome Investors, March 13, 2017
“And it has other competitive rollouts underway; the drugmaker’s hot new breast cancer seller Ibrance is about to gain new competition from Novartis, whose LEE011 could rack up $1.6 billion by 2022, EP Vantage predicts…”

Supporting the Pharma Industry Small Business Growth Engine Pharma’s Almanac, March 8, 2017
“New Report Shows Orphan Drug Market to Reach $176 Billion by 2020. EvaluatePharma. 29 Oct. 2014. Web…”

Kraftig marknadstillväxt för särläkemedel 2017-2022 Biostock, March 8, 2017
“Det fastslår Evaluate Pharma i en ny analys. Särläkemedel eller orphan drugs, betecknar sådana läkemedel som kan behandla, förebeygga eller diagnosticera livshotande eller kroniskt försvagande sjukdomar och som drabbar högst 5 av 10 000 individer…”

EP Vantage Journalist Jacob Plieth Tweets: Hearing rumour that Morgan Stanley might advise $NVO on $GBT deal. Board has authorised $NVO CEO to bid up to $45. – Benzinga, March 8, 2017

EP Vantage's Plieth tweets rumor about Global Blood deal price - The Fly, March 8, 2017
“Jacon Plieth of EP Vantage tweeted, "Hearing rumour that Morgan Stanley might advise $NVO on $GBT deal. Board has authorised $NVO CEO to bid up to $45…”

Global orphan drugs market to reach $ 209 billion by 2022Cote Orphan, March 8, 2017
“Seven of the top 10 companies by orphan drug sales are global industry players”, said Lisa Urquhart, EP Vantage editor and report contributor...”

Roche breast cancer trial success could kill Puma’s rivalPharmaphorum, March 8, 2017
“But analysts have been unimpressed with the data for neratinib, and according to EP Vantage, an FDA advisory committee could deal the drug a “fatal blow”, assuming Roche chooses to announce the data at the American Society of Clinical Oncology conference in June…”

Global orphan drugs market to reach $ 209 billion by 2022Business Standard, March 7, 2017
“Worldwide orphan drug sales forecast to total $ 209 billion (growing at CAGR of 11.1 percent from 2017 to 2022); approximately double overall prescription market growth, according to Evaluate latest report ‘EvaluatePharma Orphan Drug Report 2017’. ..”

Why are Drug Prices for Rare Diseases on the Rise? HealthLine, March 6, 2017
“According to a report on orphan drugs by EvaluatePharma, the average annual cost for orphan drugs was $111,820, compared with $23,331 for mainstream drugs…”

Orphan Drug Market to Continue Steady Growth; Sales to Double Between 2016 and 2022 AJCN, March 6, 2017
“According to EvaluatePharma’s Orphan Drug Report 2017, insurers will continue to cover orphan drugs, which will drive continued growth of the market. Sales of orphan drugs are expected to double between 2016 and 2022. By 2022, worldwide orphan drug sales are expected to total $209 billion and orphan drugs are set to be 21.4% of brand-name prescription drugs..”

The market of rare disease drugsGoinpharma, March 5, 2017
“According to a recent report by EvaluatePharma, the drug market includes 4,000 orphan drugs approved since the 1980s, with more than 300 last year, and generates approximately $114bn…”

Look back at pharma news to Mar 3The Pharma Letter, March 5, 2017
“Also commenting on Merck, EP Vantage, the editorial arm of the Evaluate group, said Merck’s $2.9 billion impairment charge on uprifosbuvir proves what many have long suspected: that the company overpaid for Idenix, effectively spending $3.9 billion on an asset it now estimates is worth just $240 million…”

UPDATE: First Woman CEO of a Global Drug Maker starts at GSK today Labiotech, March 4, 2017
“According to an EP Vantage report, she will start at a salary dramatically lower than her fellow male CEOs did during their first years on the job. Shareholders have cited a lack of experience…”

Celgene, BMS, Novartis expected to top 2022 orphan drug market worth $209B: report FierceBiotech, March 3, 2017
“The image of the plucky small biotech striving to develop treatments for the rare diseases largely ignored by big pharma is long gone,” EP Vantage editor and report contributor Lisa Urquhart said in a release accompanying the report. “Instead, this year we again find big pharma dominating the sector…”

Orphan Drugs IFPW, March 2, 2017
“Source: Edited excerpts from a report by Andreas Hadjivasiliou, an Analyst at EvaluatePharma, edited by Lisa Urquhart, Editor at EP Vantage and published by EvaluatePharma®…”

Orphan drugs will fuel pharma’s future – and a pricing pushback too Pharmaphorum, March 1, 2017
“Evaluate’s Orphan Drug Report 2017 forecasts that worldwide orphan drug sales will reach $209 billion in 2022, and will account for 21.4% of total prescription drug sales…”

Top 10 U.S. patent losses of 2017Ingenium, March 1, 2017
“To find the top U.S. patent losses for 2017, FiercePharma consulted life science commercial intelligence firm Evaluate and Drug Patent Watch, plus public securities filings, FDA records, court documents and other sources to navigate the often complicated story of intellectual property in pharmaceuticals…”

Median Cost Per Patient for Orphan Drugs is 5.5 Times Higher Than Non-Orphan Drugs PharmExec, March 1, 2017
“Highlights of the EvaluatePharma Orphan Drug Report 2017 include..”  

The top 10 orphan drugs in the late-stage pipeline Endpoints, March 1, 2017
“Every year, Evaluate crunches the numbers on the top prospects in the pipeline, and the company’s editorial arm EP Vantage includes it in their annual report on orphan drugs…”

Exponential growth expected in global medical device sector MediWorld Middle East, March 2017
“As the sector witnesses a ‘resurgence of small acquisitions’, global medical device and technology growth is to go up by 5 per cent or more annually until 2022, reaching around $530 million, market research firm Evaluate reveals…”

Rare Disease Trials: The Pros and Cons of Small Patient Groups MDGroup, March 2017
“According to EvaluatePharma, global sales of orphan drugs are forecast to grow by more than 11 per cent per year to $209bn in 2022…”

Составлен обзор глобального рынка орфанных препаратов и прогноз до 2022 г. – News.Sputnik.ru, March 2017
“Отнесение того или иного заболевания к категории редких (орфанных) зависит от числа страдающих от него пациентов, которое варьируется вразных странах, пишет EvaluatePharma…”

Pharmapills puntata n. 2. I farmaci che fattureranno di più nel 2017 Carriere Nel Farmaceutico March 2017
“Persone: Amy Brown (EP Vantage), Maurizio de Cicco (Roche), Andrea Agazzi (NMS Group), Romano Marabelli (Ministero della Salute), Dan L. Longo (Università di Harvard), Carmine Pinto (Aiom), Federica Meloni (Università di Pavia)…”

February 2017

Orphan drugs attract rich returns for pharmaceuticals – Financial Times, February 28, 2017

According to a new report by research group EvaluatePharma, there have been nearly 4,000 orphan drug designations granted by regulators in the US since the early 1980s, with more than 300 last year alone."

 

Orphan drug market growing, despite high costs Manufacturing Chemist, February 28, 2017
“Median cost per patient for orphan drugs is 5.5 times higher than non-orphan drugs, according to “EvaluatePharma Orphan Drug 2017 Report…”

 

Small patient groups hinder progress of clinical trialsFT, February 28, 2017
“Global sales of orphan drugs are forecast to grow by more than 11 per cent per year until 2022 to $209bn, according to research group EvaluatePharma…”

 

Orphan drug sales will outpace all other meds, thanks to high prices STAT News, February 28, 2017
“Based on worldwide orphan drug sales, seven of the 10 largest players are global companies, including Novartis, Roche, and AbbVie, not upstart biotechs, according to the analysis, which was conducted by EvaluatePharma, a market research firm…”

 

EP Vantage Releases its Annual Pharma and Medtech Sector Review Reports for 2016PMLive, February 28, 2017
Press release posted on site

 

Median cost per patient for orphan drugs is 5.5 times higher, report says The Pharma Letter, February 28, 2017
“The average US cost per patient per year for an orphan drug was $140,443 in 2016, compared with $27,756 for a non-orphan, according to the EvaluatePharma Orphan Drug 2017 Report…”

 

Las ventas de medicamentos huérfanos se duplicarán en los próximos cinco añosim farmacias, February 28, 2017
“La IV EvaluatePharma Orphan Drug Report reúne los análisis necesarios para entender cómo funciona y funcionará el mercado de medicamentos huérfanos desde 2017 y hasta 2022...”

 

Los medicamentos huérfanos, en torno al 22% del mercado total en 2022  - DiarioFarma, February 28, 2017
“Los datos de la consultora especializada Evaluate Pharma con respecto a la evolución de los medicamentos huérfanos son concluyentes. Y es que, pese al escaso peso que tienen en la actualidad sobre el mercado total de fármacos innovadores de prescripción, se espera que aglutinen en torno al 21,4% de éste en 2022, con unas ventas que podrían situarse en el entorno de los 209.000 millones de dólares y un crecimiento medio anual del 11,1%...”

 

Orphan drug sales will outpace all other meds, thanks to high pricesSTAT News, February 28, 2017
“Based on worldwide orphan drug sales, seven of the 10 largest players are global companies, including Novartis, Roche, and AbbVie, not upstart biotechs, according to the analysis, which was conducted by EvaluatePharma, a market research firm…”

 

These Were Big Pharma’s Biggest Winners and Losers in 2016Fortune, February 28, 2017
“Biopharma stocks endured a precipitous decline over the course of 2016. But some giants drug making giants made out far better than others, according to a new report based on data from analytics firm Evaluate…”

 

Look back at pharma news to Feb 24The Pharma Letter, February 26, 2017
Article behind paywall

 

‘Orphan drugs’ no lifeline if you can’t afford themSanta Fe New Mexican, February 26, 2017
“The top 100 orphan drugs in the U.S. cost an average of $111,820 a year per patient in 2014, according to a report by Evaluate Pharma, a market research firm…”

 

Patient death in phase 3 raises doubts about safety of Roche’s potential hemophilia blockbuster emicizumabFierceBiotech, February 24, 2017
“Emicizumab, also known as ACE910, is tipped to be a big seller for Roche—EvaluatePharma analysts predicted it will hit $1.4 billion in annual sales in 2022 last year—but the safety concerns could scuttle its attempt to unseat incumbents such as Shire…”

 

Какие лекарственные средства войдут в ТОП-10 в 2017 году?Pharm.reviews, February 24, 2017
“Компания EvaluatePharma опубликовала прогнозный рейтинг ТОП-10 препаратов по объему продаж в денежном выражении…”

 

These Were the 10 Biggest Pharmaceutical Deals of 2016 Fortune, February 24, 2017
“And that also had an effect on dealmaking, with a dearth of health care "megadeals" and a retrenchment in overall deal value, according to a new analysis by analytics firm Evaluate's EP Vantage arm…”

 

Healthcare Watch February 2017PM360, February 24, 2017
“Novo Nordisk’s once-weekly type 2 diabetes treatment semaglutide, is expected to be the most successful small-molecule drug launched in 2017, according to EvaluatePharma, a market intelligence firm that forecasts prescription drug sales…”

 

Top 10 patentów na leki, które wygasają w 2017 roku Polityka Zdrowotna, February 23, 2017
“Cialis (stosowany w leczeniu zaburzeń erekcji), którego producentem jest koncern Eli Lilly. W roku 2016 sprzedaż tego leku osiągnęła wartość 1,42 miliarda dolarów. Prognozy EvaluatePharma na rok 2022 wskazują spadek do 55 milionów dolarów…”

 

ТОП-10 ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ ПО ОБЪЕМУ ПРОДАЖ В 2017 ГОДУPharmanet.ua, February 23, 2017
“EvaluatePharma опубликовала прогнозный рейтинг ТОП-10 препаратов по объему продаж в денежном выражении. Эти препараты принесут фармкомпаниям-производителям наибольшую выручку от реализации в 2017 году…”

 

Five things for pharma marketers to know - MM&M, February 23, 2017
“EvaluatePharma estimates that Amgen's Enbrel, used to treat rheumatoid arthritis, costs nearly $45,000 for a year of treatment and Lilly's Forteo, an osteoporosis medicine, runs about $29,000 per year. (Boston Globe)…”

 

Gute Renditechancen Payoff, February 22, 2017
“Allerdings gibt es auch in Zukunft durchaus Potenzial bei ausgewählten Werten, zumal die renommierten Experten von EvaluatePharma für die verschreibungspflichtigen globalen Verkäufe bis 2022 Wachstumsraten von gut 6% prognostizieren…”

 

2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals  – Endpoints, February 22, 2017
“In a look back over a relatively quiet  year, EP Vantage, the editorial arm at Evaluate, concluded that 2016 may not have ended anywhere close to any of the records set during the boom, but I would add that the numbers reflect some considerable financial muscle that could be flexed in the year to come…”

 

Harvard Pilgrim expands use of novel drug purchasing deals Boston Globe, February 22, 2017
“Enbrel costs nearly $45,000 per patient per year in the United States, according to the research firm EvaluatePharma, while Forteo costs about $29,000 a year…”

 

Brevetti: ecco le scadenze USA del 2017 Daily Health Industry, February 22, 2017
“Nonostante l’azienda israeliana stia cercando di ritardare l’arrivo dei generici con battaglie legali, alla presentazione dei risultati del quarto trimestre del 2016 Teva ha previsto una perdita compresa tra 1 e 1,3 miliardi di dollari per Copaxone, con un eventuale arrivo dei generici sul mercato. Al secondo posto c’è Cialis, di Eli Lilly, che secondo EvaluatePharma potrebbe scendere da 1,42 miliardi di dollari incassati nel 2016 a 55 milioni di dollari nel 2022. Probabilmente le vendite resteranno alte quest’anno, ma già dal 2018 dovrebbero cominciare a calare…”

 

Top 10 U.S. patent losses of 2017 Fierce Biotech, February 21, 2017
“To find the top U.S. patent losses for 2017, FiercePharma consulted life science commercial intelligence firm Evaluate and Drug Patent Watch, plus public securities filings, FDA records, court documents and other sources to navigate the often complicated story of intellectual property in pharmaceuticals….”

 

Gilead snaps up Sarepta's priority review voucher for $125M BioPharma Dive, February 21, 2017
“Backing out other known costs from Gilead's estimates in that regulatory document, it is likely Gilead paid somewhere in the $200 million or below range for that second voucher, according to EP Vantage's Jacob Plieth…”

 

FDA APPROVES ONLY 22 NOVEL DRUGS FOR 2016. HERE IS THE TOP 10 Clinicubes, February 21, 2017
“According to EP Vantage’s 2017 preview, which has made the chart according to top sales estimates, the leader of the list is Roche’s Ocrevus (ocrelizumab)…”

 

Valeant, Alnylam & Juno shares took some of the biggest hits last year MedCity News, February 21, 2017
“The final tallies for 2016 – both the winners and the losers – were delivered Tuesday courtesy of EP Vantage, the editorial arm of life

science commercial intelligence firm Evaluate…”

 

Quel giro d’affari miliardario sulla ricerca dei farmaci orfani La Stampa, February 21, 2017
“Nel frattempo, come mostra l’Orphan drug report 2016 di Evaluate pharma, il mercato vola e raggiungerà i 182 miliardi di dollari nel 2022, marciando al ritmo del più 11,7% l’anno…”

 

Celgene to file potential MS blockbuster this yearPharmaphorum, February 20, 2017
“Analysts EP Vantage have predicted sales of around $4.4 billion by 2020…”

 

Pricing pressures in changing market landscapes: tapping the value nexusTotal Biopharma, February 21, 2017
“Evaluate Pharma projects that orphan drugs will represent more than 20.2% of global prescription sales by 2020 (excluding generics), compared with just 6.3% in 2000…”

 

Durvalumab Receives Breakthrough Therapy StatusBioPharm International, February 17. 2017
“EvaluatePharma predicts atezolizumab could receive FDA approval in 2016…”

 

El mercado oncológico liderará el sector hasta el 2022 Mirada Profesional, February 16, 2017
“Un informe de la consultora Evaluate Pharma ubica al mercado oncológico como el sector de mayor crecimiento hacia el próximo lustro. ..”

 

Ökat antal cancer- och särläkemedel de senaste 20 åren BioStock, February 15, 2017
“Ett bra exempel är världens mest inkomstbringande receptbelagda läkemedel, AbbVies Humira mot artrtit som enbart i USA drabbar 53 miljoner människor. Under 2014 sålde Humira för 11,8 miljarder dollar och 14 miljarder dollar året därpå. Evaluate Pharma förutspår att läkemedlet kommer inbringa 15,92 miljarder dollar år 2020…”

 

Senator launches investigation into FDA's orphan drug program - Advisory Board, February 15, 2017
“According to EvaluatePharma, orphan drugs currently represent seven of the 10 top-selling drugs, in terms of annual sales…”

 

ТОП-10 самых ожидаемых новых препаратов 2017 года Farmmafia, February 14, 2017
“EvaluatePharma опубликовала прогнозный рейтинг наиболее ожидаемых новых препаратов, лонч которых состоится в 2017 году. Эти препараты принесут фармкомпаниям-производителям наибольшую выручку от реализации в течение ближайших 5 лет…”

 

Darzalex var analytiker-darling i 2016 - Medwatch, February 14, 2017
Article behind paywall.

 

Can Roche's Herceptin-Perjeta combo expand yet again? Check the impending data FiercePharma, February 13, 2017
“EP Vantage noted early this year that an approval in that population would “substantially expand” the combo’s market…”

 

Therapeutic Antibodies to Track in 2017, Part IBioPharma International, February 13, 2017
“For 2017, life-science commercial intelligence firm Evaluate, in collaboration with BioPharm International, predicts that FDA may grant marketing approval to somewhere in the range of 8–16 antibody-based investigational candidates…”

 

Inmunoterapia bursátil contra el cancer El Economista, February 12, 2017
“En este sentido, Celgene es la que más atractivo guarda para los bancos de inversión. Según la consultora Evaluate Pharma, el mercado de la oncología crecerá anualmente un 12,5 por ciento hasta 2022, cuando se espera que las ventas alcancen los 190.000 millones de dólares…”

 

Sen. Grassley Opens Inquiry Into Orphan Drug Act RAPS, February 10, 2017
“According to data from EvaluatePharma, "7 of the top 10 projected worldwide best selling drugs in 2015 have an FDA-approved orphan indication..."

 

Pfizer stumbles to 4Q profit after rough year for Prevnar; what happened to industry leadership role?Monday Morning, February 9, 2017
“Now, as the key brand is expected to slow in the coming years, EvaluatePharma recently estimated that the company’s vaccines group would post an average sales increase of just 2% per year through 2022. Prevnar might gain new life in the US from a new indication in adults aged 18 to 49, granted by the FDA last year. That approval put Prevnar on tap for US adults 18 and older…”

 

LES DÉBOIRES DE 2016 VONT-ILS COÛTER CHER À SANOFI ?Societe, February 9, 2017
“Il pourrait générer 1,8 milliard de dollars de chiffre d'affaires d'ici à 2020 au total, d'après le cabinet de conseil Evaluate Pharma…”

 

Regeneron, Sanofi win reprieve from court ban on Praluent BioPharma Dive, February 9, 2017
“Evaluate Pharma predicts the drug could eventually command sales of over $4.5 billion by 2022 (which would accrue to both Sanofi and Regeneron)…”

 

15 läkemedel som kan nå blockbusterstatus år 2022 Bio Stock, February 8, 2017
“Nu har Evaluate Pharma gjort en prognos över 20 läkemedel med hög försäljningspotential som väntas nå marknad under 2017, och av dessa förutspås 15 av dem nå blockbusterstatus inom år 2022…”

 

Roche, Celgene y BMS liderarán el mercado oncológico en 2022Diagnostics News, February 6, 2017
“Así lo asegura la consultora Evaluate Pharma, que apunta a un incremento anual medio de este mercado del 12,5 por ciento en los próximos seis años. En 2015, este segmento registró unas ventas globales de 83.200 millones de dólares…”

 

Evaluate Pharma, la top ten dei farmaci che faranno il botto di vendite (nel 2022)RIF Day, February 6, 2017
“Alla domanda prova a rispondere, come a ogni inizio anno, la società specializzata americana Evaluate Pharma,  che ha stilato la classifica dei 10 farmaci che saranno lanciati nel corso del 2017 e che, a suo giudizio, raggiungeranno i fatturati più elevati al termine del prossimo quinquennio…”

 

I 10 farmaci più attesi del 2017Pharma Star, February 5, 2017
La società americana Evaluate Pharma ha stilato la classifica dei 10 farmaci che saranno lanciati nel corso del 2017 e che raggiungeranno i fatturati più elevati...”

 

Look back at pharma news to Feb 3The Pharma Letter, February 5, 2017
“Monday’s US district court ruling means that a generic version of the 40mg formulation could be on the market as soon as February, several months earlier than expected, says EP Vantage, the editorial arm of the Evaluate group…”

 

Sanofi Pasteur rolls out Quadracel in the U.S. to take on GSK's Kinrix Zerunbio, February 4, 2017
“In a September 2016 report, EvaluatePharma predicted Pentacel would be the fourth best-selling vaccine in 2022, with Pediarix trailing right behind. The report put their sales numbers that year at $1.75 billion and $1.32 billion respectively…”

 

Top 10 U.S. patent losses of 2017 FiercePharma, February 4, 2017
“Strattera will lose its patent protection May 26, according to EvaluatePharma and Drug Patent Watch. Lilly itself has guided for May 2017 but

didn’t specify a date…”

 

Brexit: Dudas, preguntas y respuestas sobre cómo afectará al sector farmacéutico-sanitario im farmacias, February 3, 2017
EP Vantage lanzaba en octubre algunas ideas de lo que podrían ser las implicaciones del Brexit para las industrias biológicas, ahora ampliadas con un nuevo estudio en colaboración con Evaluate Pharma llamado 'Brexit: Laying out a path for UK healthcare'…”

 

Fondos de inversión relacionados con la investigación del cancer Capital Radio, February 3, 2017
“Según datos de EvaluatePharma, la industria farmacéutica crecerá en un 6,3% por año, llegando a la cifra de 1,12 trillones de dólares en 2022…”

 

Quels seront les médicaments stars lancés cette année ?La Tribune, February 3, 2017
“Après l'échec des tentatives de rachat d'Actelion et de Medivation, le laboratoire français compte particulièrement sur ce potentiel blockbuster qui pourrait dépasser les 4 milliards de dollars par an en 2022, selon une étude du cabinet Evaluate Pharma...”

 

The top 15 would-be blockbusters in the pipeline prepping for a 2017 launch Endpoints, February 3, 2017
“Every year Evaluate Pharma likes to do its breakdown of the top 20 small molecules and biologics aiming to hit the market, ranked by estimated 2022 sales…”

 

В конце 2016 г. рынок слияний/поглощений в фармотрасли взял паузу перед выборами в США recipe.ru, February 3, 2017
“исключением и фармотрасль. Активность в области M&A фактически заморозилась. Исключением стали лишь две компании – Pfizer и Shire, пишет Evaluate Pharma…”

 

Компания Pfizer стала абсолютным лидером мирового фармацевтического рынка Pharma Mafia, February 2, 2017
“EvaluatePharma опубликовала прогнозный рейтинг крупнейших фармацевтических компаний в 2017 году…”

 

Ventas de medicamentos huérfanos se duplicarán en próximos 5 años PMFarma, February 1, 2017
“La IV EvaluatePharma Orphan Drug Report reúne los análisis necesarios para entender cómo funciona y funcionará el mercado de medicamentos huérfanos desde 2017 y hasta 2022…”

 

НОВАЯ ЭРА: В 2017 ГОДУ РЕЙТИНГ ТОП-10 МИРОВЫХ ФАРМКОМПАНИЙ СУЩЕСТВЕННО ИЗМЕНИТСЯ Pharm.net.ua, February 1, 2017
“EvaluatePharma опубликовала прогнозный рейтинг крупнейших фармацевтических компаний в 2017 году…”

 

Ein Jahr der Weichenstellung für die Medizintechnikbranche DeviceMed, February 1, 2017
“Obwohl laut einer Erhebung von Evaluate-MedTech noch im Jahr 2015 gerade einmal zehn Unternehmen der Medizintechnikbranche 37 Prozent des weltweiten Umsatzes auf sich vereint haben, schaut die Branche immer stärker auf Start-ups…”

Annual Report - MedAdNews, February issue
“According to recent EvaluatePharma analysis, Dupixent is forecasted to generate sales of $4.56 billion in 2022 based on its anticipated 2017 launch…”


Additional Coverage from Kaiser Health and NPR Series:
Evaluate’s dependable information on drug prices and analysis of the orphan drug market was essential to reporting for the “Orphan Drug Machine” series published on KHN.org and NPR Shots. Audio stories aired on NPR’s Morning Edition and All Things Considered. The audio stories are linked in each of the stories below.
 
Drugmakers Manipulate Orphan Drug Rules To Create Prized Monopolies -
KHN
 
Drugs For Rare Diseases Have Become Uncommonly Rich Monopolies - NPR
 
The second story, which includes the story of a patient in Connecticut, posted online with an audio story to follow.
 
Sky-High Prices For Orphan Drugs Slam American Families And InsurersKHN 


High Prices For Orphan Drugs Strain Families And Insurers - NPR


 

January 2017

Drugs For Rare Diseases Have Become Uncommonly Rich Monopolies – NPR, January 17, 2016

"Orphan drugs now account for seven of the 10 top-selling drugs of any kind, ranked by annual sales, according to EvaluatePharma."

 

2016 Saw Slump in FDA Approvals, but 2017 Could be Return to Form - PharmaPhorum, January 2, 2017
“According to Evaluate Pharma, the drug could tip $2.87 billion in revenue by 2021. Additional big hitters this year include Roche's multiple ...”

 

Healthcare Policies, R&D Investments, and Drug Approvals Will Test Bio/Pharma - Pharmaceutical Technology, January 2, 2017
“The results of the election may have shifted that opinion already, Evaluate Pharma suggests…”

 

Allergan Wraps up 2016 M&A with LifeCell Buy for $2.9 billion; Analysts Lavish Kudos all Around - Monday Morning, January 4, 2017
“The companies should be a reasonable strategic fit, says EP Vantage, with LifeCell’s tissue matrix grafts fitting with Allergan’s reconstructive breast surgery products, for example…"

 

Here’s an Infographic of Drug Patents Expiring in 2017 - BioHealth Innovation, January 5, 2017
“EP Vantage, the editorial arm of market intelligence firm Evaluate Pharma, discussed patent expirations in its 2017 pharma preview report….”

 

BD News and Analysis for Biotech and PharmaPullan’s Pieces, January 6, 2017
“Evaluate Pharma always does a good job on the state of the industry and predictions…”

 

When it Comes to PCSK9s, Payers Resisted and Sales Flopped - Medical Marketing & Media: Therapeutic Focus, January 10, 2017
“Evaluate-MedTech experts predict annual sales of cardiology-related devices will reach $62.3 billion by 2020, a 48% leap over 2015 sales of $42.1 billion . . .”

 

Look back at pharma news to Jan 6 The Pharma Letter, January 8, 2017
“In the battle for dominance in new cholesterol-fighting agents, the scenario for Amgen could scarcely be better, commented EP Vantage, the editorial arm of the Evaluate group…”

 

Top 25 Cardiovascular Brands, 2015-2016Medical Marketing & Media, January 10, 2017
“Source: sales: EvaluatePharma: journal, Kantar Media…”

 

CAR-T’s Forge Ahead, Despite Juno Death Nature Biotechnology, 10 January 2017
“Source: EP Vantage/EvaluatePharma (London)…”

 

Curevac reports another failed cancer vaccineEuropean Biotechnology, January 12, 2017
“According to pipeline analyses from EP Vantage, more than half of the agents paired with PD-1 and PD-L1 inhibitors are small molecules,

chemotherapies and established drugs…”

 

Farmaci, report di EP Vantage: nel 2016 in campo 12 blockbuster About Pharma, January 12, 2017
“Il lancio di ben 12 prodotti “blockbuster”, l’aumento della produttività, un impatto modesto delle scadenze brevettuali. Sono questi, in estrema sintesi, gli elementi principali che caratterizzeranno il mercato farmaceutico nel 2016 secondo il report “Pharma & Biotech 2016 Preview” pubblicato da EP Vantage…”

 

Cancer R&D and Drugs Dominate Pharma Deals in 2017 - Wall St Analyst, January 12, 2017
“Cancer is one of the pharmaceutical industry’s biggest markets, with worldwide sales amounting to roughly $80 billion a year and growing more than 10% annually, according to EvaluatePharma and as reported by The Wall Street Journal . . .”

 

Which Biosimilars Will Upend the Global Market in 2017?CHPI.cn, January 13, 2017
“Global Top 10 Drugs by 2017 Sales (source: EvaluatePharma)…”

 

Look back at pharma news to Jan 13 The Pharma Letter, January 15, 2017
“Takeda’s $5.2 billion takeout of Ariad Pharmaceuticals dents the hypothesis that biotechs with declining valuations will be the chief M&A targets of 2017, says EP Vantage, the editorial arm of the Evaluate group…”

 

Farmaci, report di EP Vantage: nel 2016 in campo 12 blockbuster About Pharma, January 16, 2017
“Sono questi, in estrema sintesi, gli elementi principali che caratterizzeranno il mercato farmaceutico nel 2016 secondo il report “Pharma & Biotech 2016 Preview” pubblicato da EP Vantage…”

 

Mercks F&U-chef udpeger pipeline-juvelMedWatch.dk, January 17, 2017
“Det fortæller Luciano Rossetti, der er direktør med ansvar for forskning og udvikling i koncernens biofarma-afdeling, i et interview med EP Vantage…”

 

Drugs For Rare Diseases Have Become Uncommonly Rich Monopolies - NPR, Morning Edition, January 17, 2017
“EvaluatePharma notes in its recent report that Humira, as well as a handful of other top drugs, receive less ...”

 

Look Back to Pharma News to Jan 20 - The Pharma Letter, January 22, 2017
“. . . Also commenting, EP Vantage, the editorial arm of the Evaluate group, said: Step forward Europe’s best capitalized biotech, Forward Pharma . . .”

 

Top 25 Metabolic Brands, by Sales, 2015-2016 - Medical Marketing & Media, January 23, 2017
“Source: sales, EvaluatePharma: journal, Kantar Media…”

 

When it Comes to Diabetes, Will Marketers Break with Tradition? - Medical Marketing & Media: Therapeutic Focus, January 23, 2017
“The industry needs breakthrough creative and a focus on brand building that goes beyond ‘ask your doctor if this drug is right for you’ . . . See also: Top 25 metabolic brands, by sales, 2015-2016 . . .”

 

Look back at news to Jan 27The Pharma Letter, January 29, 2017
“After taking repeated thrashings from Merck & Co in first-line lung cancer Bristol-Myers Squibb was due some good luck, commented EP Vantage, the editorial arm of the Evaluate group…”

 

Novo Nordisk strikes R&D partnership with Oxford Uni Pharmaphorum, January 30, 2017
“According to EP Vantage, sales could be as high as $2.2 billion by 2022…”

 

Autoimmune Disease Vies With Cancer to Dominate The Class Of 2017 - Seeking Alpha, January 31, 2017
“Among non-biologicals, meanwhile, the drug to watch is Novo Nordisk’s (NYSE:NVO) once-weekly semaglutide, EvaluatePharma figures suggest (see tables below)….”

 

The Top 10 Drug Launches of 2017 - FiercePharma, January 31, 2017
“After an unusually slow year for new drug approvals—the FDA greenlighted just 22 meds in 2016—it remains to be seen whether drugmakers can do much better in 2017 . . . according to EP Vantage’s 2017 preview, which ranks the year’s rollouts by 2022 sales . . .”

 

Top 5 Biologicals from European Biopharma to Launch in 2017 LaBiotech, January 31, 2017
“Still, quantitative predictions can be made for the new year. EP Vantage has put together a report summarizing what to expect from the pharma and biotech industry this year…”

 

A Look Ahead to the Top 10 Drug Launches of 2017 - MedCityNews, January 31, 2017
“Despite capturing the media’s eye, oncology drugs – including CAR-Ts – will comprise just three out of the top 10 drug launches in 2017, according to life science commercial intelligence firm Evaluate Pharma. It’s proof that headlines don’t always equate to sales. Evaluate is expecting the biggest launch of the year the field of dermatitis, with a drug for primary progressive multiple sclerosis coming in a close second . ..”

Archive

 Evaluate Buzz 2016

 Evaluate Buzz 2015

 Evaluate Buzz 2014

 Evaluate Buzz 2013

 Evaluate Buzz 2012

 Evaluate Buzz 2011